Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)

Charité University Medicine Berlin

Status and phase: Unknown; Phase 2

Conditions: Recurrent Small Cell Lung Cancer

Treatments: Drug: Bendamustin/Ribomustin

Study type: Interventional

Funder types: Other

Identifiers

NCT00168922

Haema CBF SCLC UK/AS 02

Details and patient eligibility

About

Determination of response rate Assessment of toxicity and determination of "time to progression"

Full description

Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with recurrent small cell bronchial carcinoma after cytostatic polychemotherapy

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histological proven, curative non treatable small lung cell carcinoma
• Recurrence >8 weeks, > 1 year after 1st line treatment with platin- and etoposide polychemotherapy, without brain metastases

Exclusion criteria

• Brain metastases
• WHO-PS 3 - 4

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)